Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Sunday, February 10, 2013

5th TMAU webinar : Fennessey - Preti - Reed

5th TMAU webinar provided by Rob Pleticha and See additional answers to questions on the RareConnect site.

Paul Fennessey PhD :  Recognition of TMAU as disease entity and development of choline challenge test
George Preti PhD : Evaluation of individuals with malodor problems
Danielle Reed PhD : Genetics of TMAU

Our thank you goes to Drs. Reed, Fennessey, and Preti for their informative presentation. Since there wasn't enough time for all the questions to be answered, and since they requested that viewers submit questions for them to answer, we have copied and pasted the Q & A posted at this time in RareConnect. Thanks to all guests who also participated in asking very valuable questions.

Questions and Answers that we did not have time for during the webinar

  • Mar-----: Ok, my understanding of the methylation process is when some compounds receive a methyl group, this "starts" a reaction (such as turning a gene on or activating an enzyme). When the methyl group is "lost" or removed, the reaction stops (or a gene is turned off or the enzyme is deactivated). With this in mind, couldn’t it be possible, by having a specific methylation problem, the enzyme may be deactivated, thereby causing a lack of ability to metabolize TMA?
  • Dr. Reed: It is possible that the genomic DNA which codes for FMO3 could be blocked from transcription by either DNA methylation dynamics or through modificaiton to histones - or it could be that transcription factors which initiate FMO3 transcription are lacking in some patients. Right now there is no quick test to assess human FMO3 genomic methylation because it requires liver biopsy.

link to RareConnect site where additional Q&As may be noted.


Post a Comment